Edition:
United Kingdom

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

23.95USD
8:01pm GMT
Change (% chg)

$-0.34 (-1.40%)
Prev Close
$24.29
Open
$24.31
Day's High
$24.65
Day's Low
$22.68
Volume
162,182
Avg. Vol
108,619
52-wk High
$39.26
52-wk Low
$16.43

Select another date:

Fri, Oct 27 2017

BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln ‍​

* Files for mixed shelf of up to $150 million - SEC filing‍​ Source text : [http://bit.ly/2zK9cPg] Further company coverage:

BRIEF-La Jolla reports Q3 loss $1.19/shr

* La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress

BRIEF-Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical

* Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍ Source text : [http://bit.ly/2g07Ckv] Further company coverage:

BRIEF-La Jolla Pharmaceutical Co announces intent to submit Marketing Authorization Application for LJPC-501

* La Jolla Pharmaceutical Company announces intent to submit Marketing Authorization Application for LJPC-501 in the third quarter of 2018 Source text for Eikon: Further company coverage:

BRIEF-FDA accepts La Jolla Pharmaceutical's NDA for LJPC-501

* La Jolla Pharmaceutical Company announces U.S. Fda acceptance of new drug application for LJPC-501

BRIEF-La Jolla Pharma ‍announces launch of expanded access program for LJPC-501​

* La Jolla Pharmaceutical Co - ‍announces launch of expanded access program for LJPC-501​ Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical reports CEO compensation

* CEO George Tidmarsh's 2016 total compensation was $4.7 million versus $15.6 million in 2015 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-La Jolla quarterly loss per share $1.21

* La Jolla Pharmaceutical Company announces financial results for the three and six months ended June 30, 2017 and recent corporate progress

Select another date: